Molecular forms of natriuretic peptides in heart failure and their implications

Heart

Volumn 96, Issue 6, 2010, Pages 419-424

  Xu Cai, Ye Olivia ^a   Wu, Qingyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CARDIAC GRAFT REJECTION; DIURESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION CHROMATOGRAPHY; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NATRIURESIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION; VASODILATATION;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 77949617926     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.164145     Document Type: Review

References (46)

1. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
3. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
4. Wu Q, Xu-Cai YO, Chen S, et al. Corin: new insights into the natriuretic peptide system. Kidney Int 2009;75:142-6.
5. Yan W, Wu F, Morser J, et al. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000;97:8525-9.
6. Sawada Y, Inoue M, Kanda T, et al. Co-elevation of brain natriuretic peptide and proprotein-processing endoprotease furin after myocardial infarction in rats. FEBS Lett 1997;400:177-82.
7. Koller KJ, Lowe DG, Bennett GL, et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991;252:120-3.
8. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
9. Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054-61.
10. Ogawa T, Veinot JP, Davies RA, et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 2005;24:1046-54.
11. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
12. Hunter EFM, Kelly PA, Prowse C, et al. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest 1998;58:205-16.
13. Theiss G, John A, Morich F, et al. Alpha-h-ANP is the only form of circulating ANP in humans. FEBS Lett 1987;218:159-62.
14. Yamaji T, Hirai N, Ishibashi M, et al. Atrial natriuretic peptide in umbilical cord blood: evidence for a circulating hormone in human fetus. J Clin Endocrinol Metab 1986;63:1414-17.
15. Ishizaka Y, Yamamoto Y, Tanaka M, et al. Molecular forms of human brain natriuretic peptide (BNP) in plasma of patients on hemodialysis (HD). Clin Nephrol 1995;43:237-42.
16. Cannella G, Albertini A, Assanelli D, et al. Effects of changes in intravascular volume on atrial size and plasma levels of immunoreactive atrial natriuretic peptide in uremic man. Clin Nephrol 1988;30:187-92.
17. Hasegawa K, Matsushita Y, Inoue T, et al. Plasma levels of atrial natriuretic peptide in patients with chronic renal failure. J Clin Endocrinol Metab 1986;63:819-22.
18. Akiba T, Ando K, Marumo F. Changes in molecular pattern of atrial natriuretic peptide in hemodialysis patients. Int J Artif Organs 1994;17:585-90.
19. Meleagros L, Ghatei MA, Anderson JV, et al. The presence and molecular forms of cardiodilation immunoreactivity in the human and rat right atrium. Clin Chim Acta 1988;172:199-209.
20. Yamaji T, Ishibashi M, Takaku F, et al. Nature of atrial natriuretic peptide in plasma from patients with congestive heart failure. Lancet 1986;2:402-3.
21. Ando K, Hirata Y, Emori T, et al. Circulating forms of human atrial natriuretic peptide in patients with congestive heart failure. J Clin Endocrinol Metab 1990;70:1603-7.
22. Azizi C, Maistre G, Kalotka H, et al. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. J Endocrinol 1996;148:51- 7.
23. Chimoskey JE, Spielman WS, Brandt MA, et al. Cardiac atria of BIO 14.6 hamsters are deficient in natriuretic factor. Science 1984;223:820-2.
24. Tateyama H, Hino J, Minamino N, et al. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun 1990;166:1080-7.
25. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
26. Togashi K, Hirata Y, Ando K, et al. Brain natriuretic peptide-like immunoreactivity is present in human plasma. FEBS Lett 1989;250:235-7.
27. Tateyama H, Hino J, Minamino N, et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem Biophys Res Commun 1992;85:760-7.
28. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73.
29. Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
30. Yandle TG, Richards AM, Gilbert A, et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8.
31. Hunt PJ, Espiner EA, Nicholls MG, et al. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997;18:1475-81.
32. Hawkridge AM, Heublein DM, Bergen HR 3rd, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005;102:17442-7.
33. Takahashi M, Takeda S, Kurokawa S, et al. Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure. Jpn Heart J 2003;44:713-24.
34. Dries DL. Corin, the "pro-ANP/BNP convertase" is up-regulated in human heart failure, but inversely conrrelated with BNP expression. J Card Fail 2005;11:S128.
35. Gower WR Jr, Chiou S, Skolnick KA, et al. Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 1994;15:861-7.
36. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193-202.
37. Crozier IG, Nicholls MG, Ikram H, et al. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet 1986;2:1242-5.
38. Nakajima K, Onishi K, Dohi K, et al. Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels. Int J Cardiol 2005;104:332-7.
39. Ohashi M, Fujio N, Nawata H, et al. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metab 1987;64:81-5.
40. Sato F, Kamoi K, Wakiya Y, et al. Relationship between plasma atrial natriuretic peptide levels and atrial pressure in man. J Clin Endocrinol Metab 1986;63:823-7.
41. Tan AC, Hoefnagels WH, Swinkels LM, et al. The effect of volume expansion on atrial natriuretic peptide and cyclic guanosine monophosphate levels in young and aged subjects. J Am Geriatr Soc 1990;38:1215-19.
42. Espiner EA, Nicholls MG, Yandle TG, et al. Studies on the secretion, metabolism and action of atrial natriuretic peptide in man. J Hypertens Suppl 1986;4:S85-91.
43. Predel HG, Kipnowski J, Meyer-Lehnert H, et al. Human atrial natriuretic peptide in non-dialyzed patients with chronic renal failure. Clin Nephrol 1989;31:150-5.
44. Lindberg BF, Nilsson LG, Bergquist S, et al. Radio-immunoassay of atrial natriuretic peptide (ANP) and characterization of ANP immunoreactivity in human plasma and atrial tissue. Scand J Clin Lab Invest 1992;52:447-56.
45. Hejmdal A, Boesgaard S, Lindholm MG, et al. B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. J Card Fail 2007;13:184-8.
46. Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129-35.